Johnson & Johnson (JNJ) - Stock Analysis
Last updated: Mar 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠High profitability ⢠Strong free cashflow ⢠Leverage sensitivity Johnson & Johnson delivers very high margins, exceptional returns and strong FCF supporting a steady dividend, but meaningful leverage, tight near-term liquidity and large one-time charges raise solvency and earnings-quality risks.
Price Behavior
Key Price Behavior Insights: ⢠Modest uptrend ⢠Resistance rejection ⢠Low volatility Support Level: $236.53 Resistance Level: $248.56 Over the last month JNJ has traded in a modest uptrend (â+1.6%) within a ~5% range, finding support near $236.53 but stalling at $248.56 with a recent pullback that signals limited upside until a clean breakout above $248.6 on higher volume.
Sentiment & News
Key News Insights: ⢠Oncology momentum ⢠Institutional buying ⢠$1B+ facility J&J's stock has rallied on oncology-led growth, a MedTech rebound, strong earnings and institutional accumulation, backed by a $1B+ U.S. cellâtherapy manufacturing push and technical strength.
AI Summary
JNJ is transitioning from a defensive dividend conglomerate to an innovationâled biopharma/MedTech growth story where upside now depends on successful commercialization of nipocalimab, TECVAYLI, Rybrevant and sustained MedTech margin expansion rather than yield; monitor upcoming readouts/approvals and FCF conversion after capex/M&A as the primary validation triggers. Key downside is material talc litigation and elevated leverage that could force cash outflows and derail reinvestmentâtrack litigation developments, adjusted operating FCF, and nearâterm commercial execution closely.
Description
Johnson & Johnson develops, manufactures and sells healthcare products worldwide through three principal businesses: Consumer Health, Pharmaceuticals and MedTech. Its Consumer Health unit offers household personal-care and over-the-counter medicines, the Pharmaceuticals division markets prescription therapies across immunology, infectious disease, CNS, oncology, cardiovascular and metabolic indications, and the MedTech business supplies devices for cardiovascular, neurovascular, orthopaedic, surgical and vision care. The company distributes to retailers, wholesalers, hospitals and healthcare professionals and is headquartered in New Brunswick, New Jersey; it was founded in 1886.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 23 | Jan 30 | JNJ | Johnson & Johnson | Johnson & Johnson offers robust near-term return potential backed by strong Q4 2025 results, significant FDA approvals and pipeline catalysts, plus positive short-term technical momentum supporting a bullish outlook into early 2026. | Closed | +3.2% |
| Nov 17 | Nov 24 | JNJ | Johnson & Johnson | Strong Q3 2025 beat with raised guidance, multiple near-term FDA approvals boosting revenue prospects, strategic M&A enhancing growth, robust free cash flow, and positive technical momentum just below the upper Bollinger band support a favorable near-term price appreciation setup. | Closed | +3.2% |